{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:57:45Z","timestamp":1789732665472,"version":"4.0.1"},"reference-count":43,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Background: Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with a 5-year survival rate of 10%. Irreversible electroporation (IRE), a non-thermal ablative technique, may improve outcomes in locally advanced (LAPC) and borderline resectable pancreatic cancer (BRPC). This multi-center retrospective study aims to evaluate postoperative complications, 90-day mortality, and survival following IRE. Methods: 35 pancreatic cancer patients were treated with IRE between 2015 and 2023 across three Belgian hospitals. IRE was performed for tumor destruction in unresectable LAPC (n = 13) (IRE-LAPC) and for margin accentuation during resection in BRPC (n = 22) (IRE-MA). Primary endpoints were 90-day mortality, complications, and survival (only 33 patients included); secondary endpoints included metastases, local recurrence, and R0-resection rates. Results: Postoperative complications occurred in 23.1% (IRE-LAPC) and 68.2% (IRE-MA) of patients. Overall survival at 24 months was 27.3% (IRE-LAPC) and 27.3% (IRE-MA). Median survival time was 12.7 months (IRE-LAPC) and 13.3 months (IRE-MA). Six patients (17.1%) died within 90 days. Metastasis occurred in 51.5% of patients after a median time of 9.8 months. Local recurrence was seen in 24.2% of patients after a median time of 7.5 months. R0 resection was achieved in 63.6% (IRE-MA). Discussion: IRE for margin accentuation in BRPC is associated with relatively high morbidity and mortality rates and cannot be considered beneficial. In unresectable LAPC, IRE appears relatively safe for local disease control. Further research should clarify patient selection and optimize its therapeutic role.<\/jats:p>","DOI":"10.3390\/curroncol32100574","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T07:33:50Z","timestamp":1760686430000},"page":"574","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Use of Irreversible Electroporation in Pancreatic Cancer Patients: A Multi-Center Experience"],"prefix":"10.3390","volume":"32","author":[{"given":"Bart","family":"Hendrikx","sequence":"first","affiliation":[{"name":"Department of General and HPB Surgery and Liver Transplantation, Ghent University Hospital, 9000 Gent, Belgium"},{"name":"Department of Hepatobiliary, Transplant and Endocrine Surgery, Antwerp University Hospital, 2650 Edegem, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2160-3267","authenticated-orcid":false,"given":"Eline-Alice","family":"Brys","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health Sciences, Ghent University, 9000 Gent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Dili","sequence":"additional","affiliation":[{"name":"Department of Digestive, Endocrine and General Surgery, CHU-UCL Namur, Site of Mont Godinne, 5530 Namur, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Apers","sequence":"additional","affiliation":[{"name":"Department of General and HPB Surgery and Liver Transplantation, Ghent University Hospital, 9000 Gent, Belgium"},{"name":"Department of Surgery, ZAS Hospital, 2030 Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8507-7327","authenticated-orcid":false,"given":"Vera","family":"Hartman","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary, Transplant and Endocrine Surgery, Antwerp University Hospital, 2650 Edegem, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1480-1434","authenticated-orcid":false,"given":"Martin","family":"Brichard","sequence":"additional","affiliation":[{"name":"Department of Digestive, Endocrine and General Surgery, CHU-UCL Namur, Site of Mont Godinne, 5530 Namur, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Gryspeerdt","sequence":"additional","affiliation":[{"name":"Department of General and HPB Surgery and Liver Transplantation, Ghent University Hospital, 9000 Gent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5564-1767","authenticated-orcid":false,"given":"Claude","family":"Bertrand","sequence":"additional","affiliation":[{"name":"Department of Digestive, Endocrine and General Surgery, CHU-UCL Namur, Site of Mont Godinne, 5530 Namur, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert","family":"Roeyen","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary, Transplant and Endocrine Surgery, Antwerp University Hospital, 2650 Edegem, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3575-5345","authenticated-orcid":false,"given":"Frederik","family":"Berrevoet","sequence":"additional","affiliation":[{"name":"Department of General and HPB Surgery and Liver Transplantation, Ghent University Hospital, 9000 Gent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1002\/cncr.35458","article-title":"Burden of 30 cancers among men: Global statistics in 2022 and projections for 2050 using population-based estimates","volume":"130","author":"Bizuayehu","year":"2024","journal-title":"Cancer"},{"key":"ref_2","unstructured":"World Health Organization (2025, March 24). Global Cancer Observatory. Available online: https:\/\/gco.iarc.fr\/en."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jama.2021.13027","article-title":"Pancreatic Cancer: A Review","volume":"326","author":"Park","year":"2021","journal-title":"JAMA"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1159\/000493466","article-title":"Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma","volume":"36","author":"Kaufmann","year":"2019","journal-title":"Dig. Surg."},{"key":"ref_5","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1007\/s11517-016-1603-9","article-title":"Irreversible electroporation as treatment of locally advanced and as margin accentuation in borderline resectable pancreatic adenocarcinoma","volume":"55","author":"Marsanic","year":"2017","journal-title":"Med. Biol. Eng. Comput."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.surg.2014.06.058","article-title":"Borderline and locally advanced pancreatic adenocarcinoma margin accentuation with intraoperative irreversible electroporation","volume":"156","author":"Kwon","year":"2014","journal-title":"Surgery"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Ratnayake, B., Al-Leswas, D., Mohammadi-Zaniani, G., Littler, P., Sen, G., Manas, D., and Pandanaboyana, S. (2021). Margin Accentuation Irreversible Electroporation in Stage III Pancreatic Cancer: A Systematic Review. Cancers, 13.","DOI":"10.3390\/cancers13133212"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jamcollsurg.2012.05.021","article-title":"Irreversible electroporation therapy in the management of locally advanced pancreatic adenocarcinoma","volume":"215","author":"Martin","year":"2012","journal-title":"J. Am. Coll. Surg."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/jso.24404","article-title":"Irreversible electroporation in locally advanced pancreatic cancer: A call for standardization of energy delivery","volume":"114","author":"Martin","year":"2016","journal-title":"J. Surg. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1016\/j.ejso.2021.05.024","article-title":"Margin Accentuation for resectable Pancreatic cancer using Irreversible Electroporation-Results from the MACPIE-I study","volume":"47","author":"Kundalia","year":"2021","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.surg.2022.07.033","article-title":"Impact of margin accentuation with intraoperative irreversible electroporation on local recurrence in resected pancreatic cancer","volume":"173","author":"Martin","year":"2023","journal-title":"Surgery"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"rjy127","DOI":"10.1093\/jscr\/rjy127","article-title":"Irreversible electroporation in borderline resectable pancreatic adenocarcinoma for margin accentuation","volume":"2018","author":"Papoulas","year":"2018","journal-title":"J. Surg. Case Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"8298","DOI":"10.1245\/s10434-024-15962-x","article-title":"Irreversible Electroporation Margin Accentuation in Pancreaticoduodenectomy: A Propensity Score Matching Analysis","volume":"31","author":"Lim","year":"2024","journal-title":"Ann. Surg. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"100075","DOI":"10.1016\/j.soi.2024.100075","article-title":"Impact of irreversible electroporation on survival among patients with borderline resectable\/locally advanced pancreatic cancer: A single center experience","volume":"1","author":"Suraju","year":"2024","journal-title":"Surg. Oncol. Insight"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Lafranceschina, S., Brunetti, O., Delvecchio, A., Conticchio, M., Ammendola, M., Curr\u00f2, G., Piardi, T., de\u2019Angelis, N., Silvestris, N., and Memeo, R. (2019). Systematic Review of Irreversible Electroporation Role in Management of Locally Advanced Pancreatic Cancer. Cancers, 11.","DOI":"10.3390\/cancers11111718"},{"key":"ref_17","unstructured":"NCCN Guidelines (2025, March 22). Pancreatic Adenocarcinoma. Available online: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1455."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.hpb.2021.12.014","article-title":"Multimodal therapy with or without irreversible electroporation for unresectable locally advanced pancreatic adenocarcinoma: A systematic review and meta-analysis","volume":"24","author":"Sugumar","year":"2022","journal-title":"HPB"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.surg.2023.08.042","article-title":"Multi-institutional review of adverse events associated with irreversible electroporation in the treatment of locally advanced pancreatic cancer","volume":"175","author":"Stephens","year":"2024","journal-title":"Surgery"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/SLA.0000000000001441","article-title":"Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: Safety and efficacy","volume":"262","author":"Martin","year":"2015","journal-title":"Ann. Surg."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.hpb.2018.12.004","article-title":"A prospective, multi-institution assessment of irreversible electroporation for treatment of locally advanced pancreatic adenocarcinoma: Initial outcomes from the AHPBA pancreatic registry","volume":"21","author":"Holland","year":"2019","journal-title":"HPB"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N. Eng. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/S2468-1253(24)00017-7","article-title":"MRI-guided stereotactic ablative body radiotherapy versus CT-guided percutaneous irreversible electroporation for locally advanced pancreatic cancer (CROSSFIRE): A single-centre, open-label, randomised phase 2 trial","volume":"9","author":"Timmer","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.pan.2021.04.011","article-title":"Irreversible electroporation of pancreatic cancer-Effect on quality of life and pain perception","volume":"21","author":"Flak","year":"2021","journal-title":"Pancreatology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"275","DOI":"10.21037\/jgo.2018.01.14","article-title":"Percutaneous irreversible electroporation with systemic treatment for locally advanced pancreatic adenocarcinoma","volume":"9","author":"Leen","year":"2018","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/j.jvir.2012.09.012","article-title":"Percutaneous irreversible electroporation for downstaging and control of unresectable pancreatic adenocarcinoma","volume":"23","author":"Narayanan","year":"2012","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00292-013-1799-5","article-title":"Resection margins in pancreatic cancer","volume":"34","author":"Verbeke","year":"2013","journal-title":"Pathologe"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.hpb.2023.03.016","article-title":"Prognostic significance of margin clearance in pancreaticoduodenectomy specimens with pancreatic ductal adenocarcinoma in a Danish population-based nationwide study","volume":"25","author":"Aaquist","year":"2023","journal-title":"HPB"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1177\/15533506231157442","article-title":"Irreversible Electroporation-Assisted Resection for Locally Advanced Pancreas Cancer","volume":"30","author":"Davis","year":"2023","journal-title":"Surg. Innov."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1002\/ctm2.39","article-title":"T-cell activation and immune memory enhancement induced by irreversible electroporation in pancreatic cancer","volume":"10","author":"He","year":"2020","journal-title":"Clin. Transl. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1200\/JOP.2016.016162","article-title":"Multimodality Therapy in Patients With Borderline Resectable or Locally Advanced Pancreatic Cancer: Importance of Locoregional Therapies for a Systemic Disease","volume":"12","author":"Tsai","year":"2016","journal-title":"J. Oncol. Pract."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"439","DOI":"10.6004\/jnccn.2021.0017","article-title":"Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Tempero","year":"2021","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_33","first-page":"93","article-title":"The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Brys, E.A., Gryspeerdt, F., Rashidian, N., Lerut, A.V., Dries, P., Abreu de Carvalho, L., and Berrevoet, F. (2025). Postoperative Refractory Diarrhea After Margin Accentuation of the Superior Mesenteric Artery with Irreversible Electroporation in Pancreaticoduodenectomy. J. Clin. Med., 14.","DOI":"10.3390\/jcm14103568"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.4251\/wjgo.v14.i8.1499","article-title":"Safety and feasibility of irreversible electroporation for the pancreatic head in a porcine model","volume":"14","author":"Yan","year":"2022","journal-title":"World J. Gastrointest. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1097\/MPA.0000000000001916","article-title":"Safety of Irreversible Electroporation Ablation of the Pancreas","volume":"50","author":"Lee","year":"2021","journal-title":"Pancreas"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Woeste, M.R., Wilson, K.D., Kruse, E.J., Weiss, M.J., Christein, J.D., White, R.R., and Martin, R.C.G. (2021). Optimizing Patient Selection for Irreversible Electroporation of Locally Advanced Pancreatic Cancer: Analyses of Survival. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.817220"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s11605-019-04307-9","article-title":"In-hospital Mortality Following Pancreatoduodenectomy: A Comprehensive Analysis","volume":"24","author":"Merath","year":"2020","journal-title":"J. Gastrointest. Surg."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.pan.2021.08.002","article-title":"Open irreversible electroporation for isolated local recurrence of pancreatic ductal adenocarcinoma after primary surgery","volume":"21","author":"Heger","year":"2021","journal-title":"Pancreatology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1245\/s10434-015-5034-x","article-title":"Single-Institution Experience with Irreversible Electroporation for T4 Pancreatic Cancer: First 50 Patients","volume":"23","author":"Kluger","year":"2016","journal-title":"Ann. Surg. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1159\/000375323","article-title":"Safety and feasibility of Irreversible Electroporation (IRE) in patients with locally advanced pancreatic cancer: Results of a prospective study","volume":"32","author":"Paiella","year":"2015","journal-title":"Dig. Surg."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1245\/s10434-017-5900-9","article-title":"Induction Chemotherapy Followed by Resection or Irreversible Electroporation in Locally Advanced Pancreatic Cancer (IMPALA): A Prospective Cohort Study","volume":"24","author":"Vogel","year":"2017","journal-title":"Ann. Surg. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1148\/radiol.2016152835","article-title":"Ablation of Locally Advanced Pancreatic Cancer with Percutaneous Irreversible Electroporation: Results of the Phase I\/II PANFIRE Study","volume":"282","author":"Scheffer","year":"2017","journal-title":"Radiology"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/10\/574\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T08:26:55Z","timestamp":1760689615000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/10\/574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,16]]},"references-count":43,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["curroncol32100574"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32100574","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,16]]}}}